Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap
LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce topline results from Phase 3 dry eye disease clinical trials of reproxalap. The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The access code is 127477. A live audio webcast of the conference call will also be accessible from the 'Investors & Media' section of Aldeyra's website at ir.aldeyra.com. After the live webcast, the event will remain archived on Aldeyra's website for 90 days.
About Reproxalap
Reproxalap is an investigational new drug candidate in development for the treatment of dry eye disease and allergic conjunctivitis, two of the largest markets in ophthalmology. Reproxalap is a first-in-class small-molecule modulator of RASP, which are elevated in ocular and systemic inflammatory diseases. The mechanism of action of reproxalap has been supported by the demonstration of statistically significant and clinically relevant activity in multiple physiologically distinct late-phase clinical indications. Reproxalap has been studied in more than 2,900 patients with no observed safety concerns; mild and transient instillation site irritation is the most commonly reported adverse event in clinical trials.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX‑248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Vertiv Holdings Co. (VRT) Stock Dips While Market Gains: Key Facts
The most recent trading session ended with Vertiv Holdings Co. (VRT) standing at $108.47, reflecting a -3.15% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's daily gain of 0.55%. At the same time, the Dow added 0.25%, and the tech-heavy Nasdaq gained 0.63%. The company's shares have seen an increase of 10.84% over the last month, not keeping up with the Computer and Technology sector's gain of 11.3% and outstripping the S&P 500's gain of 6.29%. The investment community will be closely monitoring the performance of Vertiv Holdings Co. in its forthcoming earnings report. It is anticipated that the company will report an EPS of $0.82, marking a 22.39% rise compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.27 billion, indicating a 16.48% increase compared to the same quarter of the previous year. VRT's full-year Zacks Consensus Estimates are calling for earnings of $3.55 per share and revenue of $9.51 billion. These results would represent year-over-year changes of +24.56% and +18.71%, respectively. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Vertiv Holdings Co. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Vertiv Holdings Co. presently features a Zacks Rank of #3 (Hold). Looking at valuation, Vertiv Holdings Co. is presently trading at a Forward P/E ratio of 31.57. This indicates a premium in contrast to its industry's Forward P/E of 19.39. We can additionally observe that VRT currently boasts a PEG ratio of 1.16. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Computers - IT Services was holding an average PEG ratio of 2.14 at yesterday's closing price. The Computers - IT Services industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 87, putting it in the top 36% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow VRT in the coming trading sessions, be sure to utilize Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vertiv Holdings Co. (VRT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
New Gold (NGD) Stock Declines While Market Improves: Some Information for Investors
In the latest market close, New Gold (NGD) reached $4.76, with a -2.06% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.55%. Elsewhere, the Dow saw an upswing of 0.25%, while the tech-heavy Nasdaq appreciated by 0.63%. Shares of the gold mining company witnessed a gain of 27.56% over the previous month, beating the performance of the Basic Materials sector with its gain of 4.58% and the S&P 500's gain of 6.29%. The investment community will be closely monitoring the performance of New Gold in its forthcoming earnings report. The company is expected to report EPS of $0.08, up 300% from the prior-year quarter. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $0.39 per share and revenue of $1.31 billion. These totals would mark changes of +95% and +41.21%, respectively, from last year. Investors might also notice recent changes to analyst estimates for New Gold. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 1.96% higher. As of now, New Gold holds a Zacks Rank of #3 (Hold). Looking at its valuation, New Gold is holding a Forward P/E ratio of 12.46. For comparison, its industry has an average Forward P/E of 12.99, which means New Gold is trading at a discount to the group. The Mining - Gold industry is part of the Basic Materials sector. Currently, this industry holds a Zacks Industry Rank of 39, positioning it in the top 16% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report New Gold Inc. (NGD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
34 minutes ago
- Yahoo
Stitch Fix (NASDAQ:SFIX) Delivers Impressive Q1, Full-Year Sales Guidance is Optimistic
Personalized clothing company Stitch Fix (NASDAQ:SFIX) reported Q1 CY2025 results beating Wall Street's revenue expectations , but sales were flat year on year at $325 million. On top of that, next quarter's revenue guidance ($300.5 million at the midpoint) was surprisingly good and 4.3% above what analysts were expecting. Its GAAP loss of $0.06 per share was 45% above analysts' consensus estimates. Is now the time to buy Stitch Fix? Find out in our full research report. Revenue: $325 million vs analyst estimates of $314.6 million (flat year on year, 3.3% beat) EPS (GAAP): -$0.06 vs analyst estimates of -$0.11 (45% beat) Adjusted EBITDA: $11.01 million vs analyst estimates of $9 million (3.4% margin, 22.4% beat) Revenue Guidance for Q2 CY2025 is $300.5 million at the midpoint, above analyst estimates of $288 million EBITDA guidance for the full year is $45 million at the midpoint, above analyst estimates of $43.93 million Operating Margin: -3%, up from -7.7% in the same quarter last year Free Cash Flow Margin: 4.9%, similar to the same quarter last year Active Clients: 2.35 million, down 280,000 year on year Market Capitalization: $609.2 million 'Stitch Fix delivered strong third quarter results, marked by our overall return to year-over-year revenue growth,' said Matt Baer, CEO, Stitch Fix. One of the original subscription box companies, Stitch Fix (NASDAQ:SFIX) is an online personal styling and fashion service that curates personalized clothing selections for customers. Reviewing a company's long-term sales performance reveals insights into its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Stitch Fix struggled to consistently generate demand over the last five years as its sales dropped at a 5.6% annual rate. This wasn't a great result and is a sign of poor business quality. We at StockStory place the most emphasis on long-term growth, but within consumer discretionary, a stretched historical view may miss a company riding a successful new product or trend. Stitch Fix's recent performance shows its demand remained suppressed as its revenue has declined by 13.6% annually over the last two years. We can better understand the company's revenue dynamics by analyzing its number of active clients, which reached 2.35 million in the latest quarter. Over the last two years, Stitch Fix's active clients averaged 16.7% year-on-year declines. Because this number is lower than its revenue growth during the same period, we can see the company's monetization has risen. This quarter, Stitch Fix's $325 million of revenue was flat year on year but beat Wall Street's estimates by 3.3%. Company management is currently guiding for a 6% year-on-year decline in sales next quarter. Looking further ahead, sell-side analysts expect revenue to remain flat over the next 12 months. While this projection suggests its newer products and services will spur better top-line performance, it is still below the sector average. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Stitch Fix's operating margin has been trending up over the last 12 months, but it still averaged negative 6.9% over the last two years. This is due to its large expense base and inefficient cost structure. In Q1, Stitch Fix generated a negative 3% operating margin. The company's consistent lack of profits raise a flag. We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Stitch Fix's earnings losses deepened over the last five years as its EPS dropped 24.5% annually. We tend to steer our readers away from companies with falling EPS, where diminishing earnings could imply changing secular trends and preferences. Consumer Discretionary companies are particularly exposed to this, and if the tide turns unexpectedly, Stitch Fix's low margin of safety could leave its stock price susceptible to large downswings. In Q1, Stitch Fix reported EPS at negative $0.06, up from negative $0.18 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street is optimistic. Analysts forecast Stitch Fix's full-year EPS of negative $0.46 will reach break even. We were impressed by how significantly Stitch Fix blew past analysts' revenue, EPS, and EBITDA expectations this quarter. We were also glad its full-year EBITDA guidance outperformed Wall Street's estimates. Zooming out, we think this was a solid print. The market seemed to be hoping for more, and the stock traded down 4.6% to $4.59 immediately after reporting. Big picture, is Stitch Fix a buy here and now? When making that decision, it's important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it's free.
